Although fourth-quarter 2020 sales of Roche Holding AG's multiple sclerosis blockbuster Ocrevus were well down on analyst forecasts, the Swiss major is confident about the drug's long-term prospects and its ability to fend off Novartis AG's newly launched rival Kesimpta.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?